Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2032-08-01
Target enrollment:
Participant gender:
Summary
This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome
(CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation
therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent
CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated
donors.